Prices are updated after-hours

Manufacturing 2

Cyteir Therapeutics Inc

CYT | $3.02 2.65% 1M

|

(0.0% 1d) (0.0% 1m) (39.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (342.66% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 108,714,165
https://cyteir.com
Sec Filling | Patents | 31 employees

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

cancer

add to watch list Paper trade email alert is off

ANGLE plc

ANPCY | News | $1.98 338.38% 930

|

(0.0% 1d) (0.0% 1m) (-44.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (568.03% volume)
Earnings Calendar:
Market Cap: $ 51,594,949
https://www.angleplc.com/
Sec Filling | Patents | n/a employees

(United Kingdom)

add to watch list Paper trade email alert is off

JTEKT Corp

JTEKY | $26.7155 2.79% 110

|

(0.0% 1m) (3.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (10.0% volume)
Earnings Calendar:
Market Cap: $ 3,057,021,778

Sec Filling | Patents | n/a employees

add to watch list Paper trade email alert is off

FLSMIDTH & CO. A/S

FLIDY | $4.53 19.1% 150

|

(0.0% 1m) (0.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-50.0% volume)
Earnings Calendar:
Market Cap: $ 2,611,545,000
http://www.flsmidth.com/
Sec Filling | Patents | n/a employees

(DK)

add to watch list Paper trade email alert is off

Femasys Inc

FEMY | $1.27 20K

|

(0.0% 1d) (-21.1% 1m) (46.1% 1y) (0.0% 2d) (0.0% 3d) (-2.3% 7d) (34.14% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 28,066,171

Sec Filling | Patents | 35 employees

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t

contraception

add to watch list Paper trade email alert is off

Nanobiotix - ADR

NBTX | $5.73 750

|

(0.0% 1d) (-6.4% 1m) (33.9% 1y) (0.0% 2d) (0.0% 3d) (6.5% 7d) (6363.92% volume)
Earnings Calendar:
Market Cap: $ 270,073,969
https://www.nanobiotix.com
Sec Filling | Patents | 89 employees

(FR) nanobiotix (euronext: nano / isin: fr0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. the company’s first-in-class, proprietary technology, nanoxray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. nanoxray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. nbtxr3 is being evaluated in: soft tissue sarcoma (sts), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). additionally, head and neck cancer and rectal cancer trials led by nanobiotix’s taiwanese partner, pharmaengine, are underway in the asia pacific region. the company started a new preclinical research program in immuno-oncology with its lea

energy

add to watch list Paper trade email alert is off

NIPPON STEEL CORP

NPSCY | News | $7.55 0.64% 0

|

(0.0% 1d) (-11.2% 1m) (1.2% 1y) (0.0% 2d) (0.0% 3d) (1.8% 7d) (131.43% volume)
Earnings Calendar:
Market Cap: $ 21,524,779,755
https://www.nipponsteel.com/
Sec Filling | Patents | 105796 employees

(JP)

add to watch list Paper trade email alert is off

Clearday, Inc.

CLRD | $0.608 18.06% 0

|

(0.0% 1d) (131.9% 1m) (-1.6% 1y) (0.0% 2d) (0.0% 3d) (17.3% 7d) (-44.7% volume)
Earnings Calendar:
Market Cap: $ 16,451,633
http://www.suptech.com/
Sec Filling | Patents | 3 employees

(US) superconductor technologies inc. (sti), headquartered in austin, tx, has been a world leader in high temperature superconducting (hts) materials since 1987, developing more than 100 patents as well as proprietary trade secrets and manufacturing expertise. for more than a decade, sti has been providing innovative interference elimination and network enhancement solutions to the commercial wireless industry. the company is currently leveraging its key enabling technologies, including rf filtering, hts materials and cryogenics to develop energy efficient, cost-effective and high performance second generation (2g) hts wire for existing and emerging power applications.

5g energy

add to watch list Paper trade email alert is off

GlobalFoundries Inc

GFS | News | $46.67 0.65% 92K

|

(0.0% 1d) (-10.6% 1m) (-24.0% 1y) (0.0% 2d) (0.0% 3d) (-2.1% 7d) (-40.9% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 25,563,725,197
http://www.globalfoundries.com/
Sec Filling | Patents | 2021 employees

(US) GLOBALFOUNDRIES Inc. operates as a semiconductor contract manufacturing and design company. The Company offers chips designed for markets such as mobility, automotive, computing and wired connectivity, and consumer internet of things (IoT). GLOBALFOUNDRIES serves customers worldwide.

msa automotive computational semiconductor chip

add to watch list Paper trade email alert is off

Kikkoman Corp

KIKOY | $24.32 3.01% 0

|

(0.0% 1d) (264.3% 1m) (-12.2% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (-15.57% volume)
Earnings Calendar:
Market Cap: $ 11,788,098,682
https://www.kikkoman.co.jp/
Sec Filling | Patents | n/a employees

(JP)

add to watch list Paper trade email alert is off

ATHENA GOLD CORP

AHNR | $0.036 -2.7% 0

|

(0.0% 1d) (29.0% 1m) (-27.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-40.57% volume)
Earnings Calendar:
Market Cap: $ 5,421,290

Sec Filling | Patents | 1 employees

athena silver corporation, an exploration stage company, engages in the acquisition and exploration of mineral resource properties in the united states. it primarily explores for silver. the company's flagship project is the langtry project that includes 20 patented and 38 unpatented lode mining claims covering an area of approximately 1,200 acres located in the central part of the mojave desert of southern california. athena silver corporation was founded in 2003 and is based in vacaville, california.

add to watch list Paper trade email alert is off

IntelGenx Technologies Corp.

IGXT | $0.1699 2.97% 0

|

(0.0% 1d) (0.9% 1m) (-2.0% 1y) (0.0% 2d) (0.0% 3d) (6.3% 7d) (-17.6% volume)
Earnings Calendar:
Market Cap: $ 29,674,411
http://www.intelgenx.com
Sec Filling | Patents | 4 employees

(CA) intelgenx is a montreal based company devoted to developing its novel and innovative proprietary technologies for enhanced drug delivery. our business strategy is to apply our proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy. intelgenx is capable, through itself and strategic partners, of offering its partners full service pharmaceutical development from formulation development, clinical development and regulatory activities to manufacturing and packaging. intelgenx’s highly qualified team has the capability to work with new chemical entities (nces) or established therapeutic active pharmaceutical ingredients (apis) where the use of innovative new drug delivery systems offer significant competitive advantage or the opportunity for product exten

add to watch list Paper trade email alert is off

Standard BioTools Inc

LAB | $2.585 1.77% 140K

|

(0.0% 1d) (-5.9% 1m) (47.7% 1y) (0.0% 2d) (0.0% 3d) (-2.7% 7d) (-16.98% volume)
Earnings Calendar:
Market Cap: $ 749,954,849
https://www.fluidigm.com
Sec Filling | Patents | 627 employees

(US) Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all.

immunotherapy cancer animals

add to watch list Paper trade email alert is off

Lisata Therapeutics Inc

LSTA | $2.67 5.7K

|

(0.0% 1d) (-18.6% 1m) (-19.6% 1y) (0.0% 2d) (0.0% 3d) (-4.0% 7d) (-4.1% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 22,180,846
https://www.caladrius.com
Sec Filling | Patents | 24 employees

(US) Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).

treatment msa kidney lungs t-cell covid

add to watch list Paper trade email alert is off

Singing Machine Co., Inc.

MICS | $0.88 610

|

(0.0% 1d) (-10.2% 1m) (-40.1% 1y) (0.0% 2d) (0.0% 3d) (18.9% 7d) (871.46% volume)
Earnings Calendar:
Market Cap: $ 5,647,894

Sec Filling | Patents | 32 employees

it all started with a vision… singing machine was founded in 1982 in california as a manufacturer of professional and semi-professional karaoke machines. in 1988, our founder eddie steele saw potential in home karaoke machines and the results speak for themselves. singing machine became the first company to introduce home karaoke products to the united states earning us the spot as the most recognized karaoke brand and as such, singing machine products incorporate the latest technology for singing practice, music listening, entertainment and social sharing. today, we are the north american leader in consumer karaoke products and have grown at an explosive rate of 20% year-over-year. we offer the industry’s widest line of at-home karaoke machines, accessories, and music-oriented toy products at affordable price points that represent tremendous value to our customers as well as over 14,000 songs for streaming and download with apps available for ios and android. singing machine products

add to watch list Paper trade email alert is off

NewHydrogen, Inc.

NEWH | $0.007 9.2M

|

(0.0% 1d) (38.9% 1m) (-17.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (82.16% volume)
Earnings Calendar:
Market Cap: $ 4,932,197

Sec Filling | Patents | 2 employees

add to watch list Paper trade email alert is off

NIDEC CORP

NJDCY | News | $11.0 210K

|

(0.0% 1d) (5.7% 1m) (-13.4% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (93.62% volume)
Earnings Calendar:
Market Cap: $ 26,236,516,592
https://www.nidec.com/
Sec Filling | Patents | n/a employees

(JP)

add to watch list Paper trade email alert is off

Nutex Health Inc

NUTX | $0.6894 29K

|

(0.0% 1d) (566.7% 1m) (11.3% 1y) (0.0% 2d) (0.0% 3d) (4.5% 7d) (-47.14% volume)
Earnings Calendar:
Market Cap: $ 513,897,277

Sec Filling | Patents | 14 employees

nutex health is a consortium of licensed 24/7 free standing emergency centers. our philosophy is simple: bring concierge level, high quality emergency care to the local community. we build the best teams of local doctors and nursing staff and provide the best medical care for our patients in a convenient and friendly atmosphere. currently in austin, beaumont, dallas, eagle pass, kyle, laredo, lufkin, richmond, san angelo, texarkana, & victoria.

add to watch list Paper trade email alert is off

Navitas Semiconductor Corp

NVTS | $3.785 3.13% 310K

|

(0.0% 1d) (-17.2% 1m) (-43.0% 1y) (0.0% 2d) (0.0% 3d) (-5.9% 7d) (-11.78% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 678,473,294
https://navitassemi.com
Sec Filling | Patents | 4 employees

(US) Navitas Semiconductor is the industry leader in GaN power ICs, founded in 2014. GaN power ICs integrate GaN power with drive, control and protection to enable faster charging, higher power density and greater energy savings for mobile, consumer, enterprise, eMobility and new energy markets. Over 130 Navitas patents are issued or pending, and over 30 million GaNFast power ICs have been shipped with zero reported GaN field failures. Navitas rang the Nasdaq opening bell and started trading on Nasdaq on October 20th, 2021, with an enterprise value over $1B and over $320M gross capital raise.

energy semiconductor

add to watch list Paper trade email alert is off

Nuvve Holding Corp

NVVE | News | $0.7173 2.2K

|

(0.0% 1d) (-16.8% 1m) (20.6% 1y) (0.0% 2d) (0.0% 3d) (9.1% 7d) (146.88% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 4,353,949
https://nuvve.com
Sec Filling | Patents | 21 employees

Nuvve is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. Its mission is to lower the cost of electric vehicle ownership while supporting the integration of renewable energy sources, including solar and wind. Nuvve’s Grid Integrated Vehicle, GIVe™, platform is refueling the next generation of electric vehicle fleets through intelligent, bidirectional charging solutions. Since its founding in 2010, Nuvve has launched successful V2G projects on five continents and is deploying commercial services worldwide by developing partnerships with utilities, automakers, and electric vehicle fleets

energy electric vehicles solar vehicles renewable eletrical

add to watch list Paper trade email alert is off

← Previous
1
2
Next →

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

87%

13%

Top 10 Gainers

MTTR | News M | $4.625 165.81% 5.5M

|

AGBA | $2.46 96.8% 28M

|

EDBL | News | $6.94 84.57% 1.4M

|

CZOO | $7.74 55.11% 2.7M

|

PALI | $7.64 54.97% 14M

|

OPRT | News | $3.19 41.78% 3M

|

PEGY | $0.0629 37.34% 110M

|

ZAPP | $6.02 35.59% 95K

|

MLEC | $1.87 33.57% 1.6M

|

ATGL | $3.66 27.97% 150K

|

Last 48 Hours Insiders Buying

ETST P 79000 | $0.065 18.18% 0

|

| 11:30
MCFT P 26039 | $21.555 0.26% 17K

|

Consumer Durables

| 00:00
YORW P 29 | $35.42 8K

|

| 19:01
VUZI P 14500 | $1.35 48K

|

Electronic Technology

| 17:00
BANF P 256 | $92.6 1.45% 2.3K

|

| 15:30
RMCF | $3.57 43

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar